Psoriasis

Some oncologists refrain from prescribing checkpoint immunotherapy in patients with Kaposi sarcoma who also have psoriasis or other skin conditions. A new case report says the therapy can be successfully completed while still controlling the skin condition.

Platelet function may aid in determining disease severity for patients with psoriasis who are at an increased risk of developing cardiovascular disease (CVD) and increased inflammation, a review notes.

Guidelines created by the American Academy of Dermatology (AAD) and the National Psoriasis Foundation (NPF) address care management and treatment options for patients with psoriasis in relation to the increased risk of developing inflammatory, cardiovascular, and metabolic conditions.

A new review article finds patients who suffer from psoriatic arthritis (PsA) face a higher risk of type 2 diabetes (T2D), though the exact reasons for the linkage are not yet clear.

Investigators still have a lot to learn about the links among psoriatic arthritis, inflammation, and depression, but a growing body of evidence suggests significant interplay.

A range of new research is helping scientists better understand psoriasis while also raising new questions. One approach is looking at how the gut microbiome affects the disease.

A number of advances have been made in recent years in our understanding of the genetics of psoriatic diseases and psoriatic arthritis specifically. However, those advances have yet to translate into clinically meaningful insights.

Psoriasis typically emerges among the young, while Alzheimer disease is mainly a disorder of old age, raising the question of whether psoriasis has an impact on the later development of neurodegenerative diseases.

The study, with a small sample size, said most patients who take infliximab for more than 6 years report continued efficacy.

In a recently published review, researchers examined the brain-skin connection and the pathogenesis of psoriasis, focusing on the serotonergic system.

Limited data about the effects of psoriasis therapy during pregnancy make it difficult to know which options are possible for pregnant patients and which ones can be harmful, according to a review.

Researchers found a frequent association of depression with psoriasis and atopic dermatitis, according to a descriptive-explorative and retrospective study published in Psychiatry Investigation.

Overall, however, the FDA has reported 12 cases of dyshidrotic eczema caused by secukinumab, the investigators noted.

Research has suggested patients with psoriasis are at a higher risk of hypertension, but a recent meta-analysis aimed to prove the case by looking at tens of thousands of cases.

The combination of the biologic adalimumab and hydroxychloroquine may be responsible for the improvement in lichen planopilaris, including the hair regrowth, according to the study.

The results are in line with earlier studies, and the current review found a link with bladder cancer and lung cancer.

Patients undergoing immunotherapy could be at risk for psoriasis flare-ups, even if the patient is asymptomatic at the initiation of cancer treatment. A newly published case report outlines a rare case where immunotherapy had to be stopped due to severe skin lesions.

Dose reduction of biologics adalimumab, etanercept, and ustekinumab was not shown to be as effective as providing the usual doses for treatment of psoriasis, according to study findings published today.

New research finds salivary antioxidants and oxidative stress could be important biomarkers for plaque psoriasis.

In a meta-analysis comparison of biologics and oral treatments for moderate to severe plaque psoriasis, results suggest that brodalumab, guselkumab, ixekizumab, and risankizumab-rzaa were associated with the highest response rates in both short-term and long-term therapy.

Researchers exhibit recent advances in the basic characteristics of interleukin (IL)-24, a member of the IL-20 family of cytokines associated with pro-inflammatory autoimmune disorders such as psoriasis, arthritis, and inflammatory bowel diseases, as a catalyst in the pathogenesis of allergic skin inflammation.

A formulation of calcipotriene and betamethasone dipropionate cream met its primary endpoint for treating plaque psoriasis during its phase 3 trial in the European Union, according to an announcement from MC2 Therapeutics.

Researchers outline the significant role IL-37 plays in psoriasis, and other skin and connective tissue diseases, suggesting the need for further research, according to a review.

Compared with other biologics approved for psoriasis treatment, excluding recently approved biologics, ixekizumab and brodalumab were shown to have greater cumulative clinical benefit for patients with psoriasis, according to study findings.

Researchers outlined a comprehensive review of the common mechanisms through which interleukin-17 (IL-17) is considered a molecular target for developing novel biological therapies in several different fields of medicine, according to report findings.

While prevalence rates of psoriasis are lower among the Latino population compared with the white and black populations in the United States, Latinos are shown to be disproportionately affected by poorer quality of life and intensified disease severity, according to study findings.

The researchers said that they are the first to demonstrate elevated concentrations of serum fibroblast growth factor 21 (FGF21) in patients with plaque-type psoriasis.

A recently published review in Frontiers in Immunology highlights the efficacy of Janus kinase inhibitors as treatments for several dermatological ailments, including psoriasis. Authors described how newly researched pathologic factors have changed therapeutic practices used to treat inflammation and autoimmunity.

Current categories of classifying psoriasis, such as mild, moderate, or severe, do not consider past treatments or involvement of special areas, leading to undertreatment, a report said.

The investigational therapy, an interleukin (IL)-17A and IL-17F inhibitor, is the third phase 3 study of bimekizumab to report positive results since October, following BE VIVID and BE READY, which evaluated the safety and efficacy of the drug.